The U.S. FDA has finalized a rewritten draft guidance for Section 522 postmarket surveillance studies, a policy that carries a new level of stringency regarding how these studies are conducted. The final guidance calls for all subjects in such a study to be enrolled within 24 months, a deadline some in industry argued might prove unduly burdensome in some instances.